Medication info
Sotec 40 mg (Esomeprazole Magnesium Trihydrate)

Sotec 40 mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›44.5mg / 1 tablet
Manufacturer / importer
Daewon Biotech Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
For domestic use - 28 tablets/box [(14 tablets/PTP*2)], for export - 28 tablets/box [(14 tablets/PTP*2)]
Approval status
Active

MFDS item code 201905342 · Approved 2019.07.29 · Insurance code 057600110

Summary

Main use
Treatment of acid-related disorders (reflux, Zollinger-Ellison syndrome), ulcers and Helicobacter pylori infection, and drug-induced gastrointestinal disorders
Who uses it
Adults · Children
Adult dosage
This medicine should be swallowed with a liquid such as water and should not be chewed or crushed. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis is not healed or symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. · Once symptoms have resolved, control subsequent symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for control of recurring symptoms in patients at high risk of gastric and duodenal ulcers due to administration of nonsteroidal anti-inflammatory drugs. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, and heartburn) associated with administration of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. No clinical trials longer than 4 weeks have been conducted. 4) Patients requiring continuous administration of nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should subsequently be adjusted for each patient, and treatment should continue while clinical symptoms are present. According to clinical data, most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided into 2 doses. 6) Maintenance therapy after induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration Administer 40 mg once daily for 4 weeks after induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration. 4. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience administering this medicine to patients with severe renal impairment. 5. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Elderly patients: No dose adjustment is necessary.
Children's dosage
2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis is not healed or symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. · Once symptoms have resolved, control subsequent symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for control of recurring symptoms in patients at high risk of gastric and duodenal ulcers due to administration of nonsteroidal anti-inflammatory drugs. 3. Children under 12 years of age: There is no experience with administration of this medicine to children under 12 years of age.

Ingredients

Manufacturer
Daewon Biotech Co., Ltd.

Efficacy & effects

Treatment of acid-related disorders (reflux, Zollinger-Ellison syndrome), ulcers and Helicobacter pylori infection, and drug-induced gastrointestinal disorders

  • Gastroesophageal reflux disease
  • erosive esophagitis
  • esophagitis
  • benign duodenal ulcers associated with Helicobacter pylori
  • peptic ulcers
  • upper gastrointestinal symptoms
  • pain
  • discomfort
  • burning sensation
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
View approved original text

This medicine is used for the treatment and symptom relief of esophagitis caused by gastroesophageal reflux disease, as well as for the treatment and prevention of recurrence of duodenal and peptic ulcers caused by Helicobacter pylori infection. It is also effective in treating gastrointestinal symptoms due to non-steroidal anti-inflammatory drug administration, as well as gastric and duodenal ulcers. It is utilized as maintenance therapy to prevent rebleeding of gastric or duodenal ulcers after intravenous injection. It is widely used for various gastrointestinal-related diseases, aiding in symptom improvement and health recovery for patients.

Dosage and Administration

Adult dosage

This medicine should be swallowed with a liquid such as water and should not be chewed or crushed. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis is not healed or symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. · Once symptoms have resolved, control subsequent symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for control of recurring symptoms in patients at high risk of gastric and duodenal ulcers due to administration of nonsteroidal anti-inflammatory drugs. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, and heartburn) associated with administration of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. No clinical trials longer than 4 weeks have been conducted. 4) Patients requiring continuous administration of nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should subsequently be adjusted for each patient, and treatment should continue while clinical symptoms are present. According to clinical data, most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided into 2 doses. 6) Maintenance therapy after induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration Administer 40 mg once daily for 4 weeks after induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration. 4. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience administering this medicine to patients with severe renal impairment. 5. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Elderly patients: No dose adjustment is necessary.

Children's dosage

2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis is not healed or symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. · Once symptoms have resolved, control subsequent symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for control of recurring symptoms in patients at high risk of gastric and duodenal ulcers due to administration of nonsteroidal anti-inflammatory drugs. 3. Children under 12 years of age: There is no experience with administration of this medicine to children under 12 years of age.

Precautions

This medicine is used to treat gastrointestinal diseases by suppressing gastric acid secretion. Some patients may experience side effects such as allergic reactions or skin rashes, headaches, dizziness, and gastrointestinal disturbances after taking this medicine. You should not take this medicine if you are allergic to this medicine, its ingredients, or certain antibiotics. Additionally, it is advisable for individuals with heart disease or nursing women to avoid using this medicine. Long-term users should have regular examinations to ensure no unusual symptoms occur. This medicine may interact with other drugs, so you must inform your doctor or pharmacist if you are taking any other medications. The safety of this medicine during pregnancy has not been sufficiently confirmed, so caution is advised. In case of overdose, there is no specific antidote, so treatment should be based on symptoms, and it should be kept out of reach of children.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucination, headache, dizziness, paresthesia, drowsiness, taste disorder, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, jaundice, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, Lyell's syndrome, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distension, allergic reaction, back pain, chest pain, sternal pain, facial edema, facial flushing, fatigue, fever, influenza-like illness, general edema, leg edema, malaise, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, thyroid goiter, irritable bowel syndrome, exacerbation of constipation, indigestion, dysphagia, gastrointestinal malformation, upper abdominal pain, belching, esophageal disorder, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, black stools, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, tongue disorders, tongue edema, ulcerative stomatitis, vomiting, otalgia, tinnitus, anemia, hypochromic anemia, cervical lymphadenopathy, nosebleed, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver function abnormalities, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, polydipsia, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, seizures, fibromyalgia syndrome, hernia, rheumatoid polymyalgia, arthralgia, loss of appetite, apathy, increased appetite, confusion, worsening depression, hypertonia, anxiety, sensory loss, erectile dysfunction, insomnia, migraine, worsening migraine, sleep disorder, tremors, dizziness, visual field loss, paresthesia, drowsiness, dysmenorrhea, menstrual disorders, vaginitis, worsening asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, rash, erythematous rash, papular rash, angioedema, dermatitis, itching, urticaria, increased sweating, otitis media, olfactory disturbance, taste loss, taste distortion, abnormal urination, albuminuria, cystitis, dysuria, fungal infection, hematuria, frequency of urination, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyp or nodule, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine may be sensitive to air and moisture, so it should be stored in a tightly closed container. It is best to maintain the storage temperature between 1 to 30 degrees Celsius. Proper storage preserves the drug's efficacy and safety for an extended period.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

For domestic use - 28 tablets/box [(14 tablets/PTP*2)], for export - 28 tablets/box [(14 tablets/PTP*2)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.